)
)
Cassava Sciences Investor Relations Material
Latest events
Status Update
Cassava Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Cassava Sciences Inc
Access all reports
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s leading drug candidate, simufilam, is an oral small molecule in 3 clinical trials aimed at treating Alzheimer’s by targeting an altered form of a brain protein known as filamin A. Cassava Sciences is also developing SavaDx, an investigational diagnostic tool designed to detect Alzheimer's disease through a blood test. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
SAVA
Country
🇺🇸 United States